DK630789D0 - Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af autoimmune sygdomme - Google Patents

Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af autoimmune sygdomme

Info

Publication number
DK630789D0
DK630789D0 DK630789A DK630789A DK630789D0 DK 630789 D0 DK630789 D0 DK 630789D0 DK 630789 A DK630789 A DK 630789A DK 630789 A DK630789 A DK 630789A DK 630789 D0 DK630789 D0 DK 630789D0
Authority
DK
Denmark
Prior art keywords
nalmefen
naltrexon
medicine
prepare
immune diseases
Prior art date
Application number
DK630789A
Other languages
English (en)
Other versions
DK630789A (da
Inventor
David C Atkinson
Fred P Sherman
Original Assignee
Baker Cummins Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharma filed Critical Baker Cummins Pharma
Publication of DK630789D0 publication Critical patent/DK630789D0/da
Publication of DK630789A publication Critical patent/DK630789A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK630789A 1988-12-15 1989-12-13 Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af autoimmune sygdomme DK630789A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/284,615 US4857533A (en) 1988-12-15 1988-12-15 Method of treatment for autoimmune diseases

Publications (2)

Publication Number Publication Date
DK630789D0 true DK630789D0 (da) 1989-12-13
DK630789A DK630789A (da) 1990-06-16

Family

ID=23090868

Family Applications (1)

Application Number Title Priority Date Filing Date
DK630789A DK630789A (da) 1988-12-15 1989-12-13 Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af autoimmune sygdomme

Country Status (11)

Country Link
US (1) US4857533A (da)
EP (1) EP0373744B1 (da)
JP (1) JPH07555B2 (da)
AT (1) ATE107508T1 (da)
AU (1) AU617494B2 (da)
CA (1) CA1333569C (da)
DE (1) DE68916387T2 (da)
DK (1) DK630789A (da)
IL (1) IL92269A (da)
NO (1) NO894942L (da)
ZA (1) ZA899028B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013739A (en) * 1986-10-07 1991-05-07 Bernard Bihari Method of treating chronic fatigue syndrome using an opiate receptor antagonist
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
JP2906654B2 (ja) * 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5376662A (en) * 1993-12-08 1994-12-27 Ockert; David M. Method of attenuating nerve injury induced pain
SE9304236D0 (sv) * 1993-12-22 1993-12-22 Astra Ab New use
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
DK2368553T3 (da) 2003-04-08 2015-02-09 Progenics Pharm Inc Lægemiddelsammensætning der omfatter methylnaltrexon
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
SI2379066T1 (sl) * 2008-09-16 2014-08-29 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Uporaba opioidnih antagonistov za pripravo zdravila za zdravljenje degenerativnih bolezni retine
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
ES2861774T3 (es) 2015-12-22 2021-10-06 Zogenix International Ltd Composiciones de fenfluramina y procedimientos para prepararlas
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
JP2022547619A (ja) 2019-09-16 2022-11-14 フィジーン、エルエルシー 椎間板変性疾患の治療、及び繊維芽細胞ならし培地によるタンパク質グリカン合成の刺激、並びにその製剤
CA3208374A1 (en) * 2021-03-09 2022-09-15 Ju Hee Kim Sustained formulation for prevention or treatment of autoimmune disease containing naltrexone and method using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
DK160590C (da) * 1988-09-12 1991-09-16 Fls Airloq As Fremgangsmaade til detektering af en gasart ved hjaelp af fotoakustisk spektroskopi
US4877791A (en) * 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases

Also Published As

Publication number Publication date
IL92269A (en) 1994-04-12
ZA899028B (en) 1990-08-29
US4857533A (en) 1989-08-15
EP0373744B1 (en) 1994-06-22
JPH02184627A (ja) 1990-07-19
DE68916387D1 (de) 1994-07-28
CA1333569C (en) 1994-12-20
DE68916387T2 (de) 1994-10-13
AU617494B2 (en) 1991-11-28
ATE107508T1 (de) 1994-07-15
NO894942D0 (no) 1989-12-08
EP0373744A3 (en) 1991-09-18
NO894942L (no) 1990-06-18
EP0373744A2 (en) 1990-06-20
IL92269A0 (en) 1990-07-26
AU3827989A (en) 1990-06-21
DK630789A (da) 1990-06-16
JPH07555B2 (ja) 1995-01-11

Similar Documents

Publication Publication Date Title
DK630789D0 (da) Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af autoimmune sygdomme
EP0377272A3 (en) Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases
DK541189A (da) Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af interstitiel cystitis
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
ATE67677T1 (de) Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
MX9203543A (es) Medicamento.
NO173726C (no) Fremgangsmaate for fremstilling av et oralt terapeutisk system for administrering av karbamazpin
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
IT1240360B (it) Uso di un derivato dell'1alfa-idrossivitamina d per la preparazione di un medicamento per il trattamento dell' iperparatiroidismo
DE68900994D1 (de) Diphosphonsaeurederivat enthaltendes arzneimittel zur oralen gabe.
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
DE69113921D1 (de) Verwendung eines reinen Opiatantagonisten, z.B. Nalmefen, Naltrexon, Naloxon oder Diprenorphin, zur Behandlung von Mastzell-Erkrankungen.
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
ATE2272T1 (de) 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2b)thiophen-4,9-imine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
ATA264087A (de) Pharmazeutische praeparate zur oralen verabreichung
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
NO882983L (no) Oral doseringsform for interferon for menneskelig bruk.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment